oncteranl logo
  • About
    • Overview
    • Leadership
  • Pipeline
    • Overview
    • ONCT-808
    • ONCT-534
    • Zilovertamab
  • Science
    • Overview
    • Publications
  • Patients
  • Careers
    • Current Opportunities
    • Vision, Mission and Impact
  • Contact

Product Pipeline

  • About
    • Overview
    • Leadership
  • Pipeline
    • Overview
    • ONCT-808
    • ONCT-534
    • Zilovertamab
  • Science
    • Overview
    • Publications
  • Patients
  • Careers
    • Current Opportunities
    • Vision, Mission and Impact
  • Contact

Clinical-Stage Products Focused on Novel Targets

Oncternal Therapeutics is a clinical-stage oncology company developing potentially first-in-class, novel therapies that target a broad spectrum of cancers with large unmet medical need. By leveraging pathways absent or minimally expressed in normal cells or tissue, we aim to impact cancer cell growth while reducing potential harm to healthy cells. We continue to investigate the potential to treat additional malignancies with our product candidates and intend to broaden the indications we are studying.

Pipeline-Sep24

On September 12, 2024, Oncternal announced it was discontinuing its clinical trials and exploring strategic alternatives.

BACK TO HOME

Contact

© 2016 - 2025 Oncternal Therapeutics. All rights reserved

logo
  • About
    • Overview
    • Leadership
  • Pipeline
    • Overview
    • ONCT-808
    • ONCT-534
    • Zilovertamab
  • Science
    • Overview
    • Publications
  • Patients
  • Careers
    • Current Opportunities
    • Vision, Mission and Impact
  • Contact